Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Watching Uxin; Zacks Small-Cap Research Sets $2.15 Price Valuation

Watching Uxin; Zacks Small-Cap Research Sets $2.15 Price Valuation

Zacks_SCR_Research_10172022_UXIN_Kerr.pdf

byBenzinga Newsdesk

October 17, 2022

1 minute read

Zacks_SCR_Research_10172022_UXIN_Kerr.pdf

Is Apple’s Vision Pro Headset Worth It? Top Tech Reviewer Gives Honest Review

By Ananya Gairola

June 6, 8:45 AM

On Monday, during its annual AAPL) revealed the highly anticipated Vision Pro mixed reality headset. However, the device comes with a…

AAPL

Why Bellicum Pharmaceuticals Stock Is Plunging Today

By Vandana Singh

February 16, 11:53 AM

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) announced the presentation of early Phase 1 results for BPX-601 at the American Society of Clinical Oncology…

BLCM

Barclays Maintains Overweight on Lumentum Holdings, Lowers Price Target to $95

By Benzinga Newsdesk

July 25, 7:07 AM

Barclays analyst Tom O'Malley maintains Lumentum Holdings (NASDAQ:LITE) with a Overweight and lowers the price target from $100 to $95.

LITE

Vuzix Expands Asia-Pacific Presence With Order From Distribution Partner HongKe

By Shivani Kumaresan

October 11, 2:32 PM

Vuzix Corp (NASDAQ:VUZI) has received and shipped against a volume purchase order from HongKe Technology Co Ltd, a distributor based in Guangzhou,…

VUZI

Watching Uxin; Zacks Small-Cap Research Sets $2.15 Price Valuation

Related Posts

Is Apple’s Vision Pro Headset Worth It? Top Tech Reviewer Gives Honest Review

Why Bellicum Pharmaceuticals Stock Is Plunging Today

Barclays Maintains Overweight on Lumentum Holdings, Lowers Price Target to $95

Vuzix Expands Asia-Pacific Presence With Order From Distribution Partner HongKe